Skip Nav Destination
Issues
15 April 2013
-
Cover Image
Cover Image
![issue cover]()
The cover shows a section from a plasmacytoma that was resected from a patient with advanced multiple myeloma. Immunohistochemistry staining revealed that the malignant plasma cells expressed B-cell maturation antigen. For details, see the article by Carpenter and colleagues on page 2048 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
Molecular Pathways
Tobacco Statement
Human Cancer Biology
Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88)
Hidetoshi Nitta; Yoshihiro Wada; Yoshiaki Kawano; Yoji Murakami; Atsushi Irie; Keisuke Taniguchi; Ken Kikuchi; Gen Yamada; Kentaro Suzuki; Jiro Honda; Masayo Wilson-Morifuji; Norie Araki; Masatoshi Eto; Hideo Baba; Takahisa Imamura
Cancer Therapy: Preclinical
Targeting the NF-κB and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKKβ for Pancreas Cancer Therapy
Prakash Radhakrishnan; Vashti C. Bryant; Elizabeth C. Blowers; Rajkumar N. Rajule; Nagsen Gautam; Muhammad M. Anwar; Ashley M. Mohr; Paul M. Grandgenett; Stephanie K. Bunt; Jamie L. Arnst; Subodh M. Lele; Yazen Alnouti; Michael A. Hollingsworth; Amarnath Natarajan
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Emanuela Leone; Eugenio Morelli; Maria T. Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C. Munshi; Kenneth C. Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Ymera Pignochino; Carmine Dell'Aglio; Marco Basiricò; Federica Capozzi; Marco Soster; Serena Marchiò; Stefania Bruno; Loretta Gammaitoni; Dario Sangiolo; Erica Torchiaro; Lorenzo D'Ambrosio; Franca Fagioli; Stefano Ferrari; Marco Alberghini; Piero Picci; Massimo Aglietta; Giovanni Grignani
Imaging, Diagnosis, Prognosis
Mammographic Breast Density Response to Aromatase Inhibition
Celine M. Vachon; Vera J. Suman; Kathleen R. Brandt; Matthew L. Kosel; Aman U. Buzdar; Janet E. Olson; Fang-Fang Wu; Lynn M. Flickinger; Giske Ursin; Catherine R. Elliott; Lois Shepherd; Richard M. Weinshilboum; Paul E. Goss; James N. Ingle
Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy
Ali Sadeghi-Naini; Naum Papanicolau; Omar Falou; Judit Zubovits; Rebecca Dent; Sunil Verma; Maureen Trudeau; Jean Francois Boileau; Jacqueline Spayne; Sara Iradji; Ervis Sofroni; Justin Lee; Sharon Lemon-Wong; Martin Yaffe; Michael C. Kolios; Gregory J. Czarnota
Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment
Marlinda Adham; Astrid E. Greijer; Sandra A.W.M. Verkuijlen; Hedy Juwana; Sabine Fleig; Lisnawati Rachmadi; Octavia Malik; A.N. Kurniawan; Averdi Roezin; Soehartati Gondhowiardjo; Djumhana Atmakusumah; Servi J.C. Stevens; Bambang Hermani; I. Bing Tan; Jaap M. Middeldorp
CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Dorian R.A. Swarts; Mieke E.R. Henfling; Leander Van Neste; Robert-Jan van Suylen; Anne-Marie C. Dingemans; Winand N.M. Dinjens; Annick Haesevoets; Martina Rudelius; Erik Thunnissen; Marco Volante; Wim Van Criekinge; Manon van Engeland; Frans C.S. Ramaekers; Ernst-Jan M. Speel
An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma
Quynh-Thu Le; Qiang Zhang; Hongbin Cao; Ann-Joy Cheng; Benjamin A. Pinsky; Ruey-Long Hong; Joseph T. Chang; Chun-Wei Wang; Kuo-Chien Tsao; YM Dennis Lo; Nancy Lee; K. Kian Ang; Anthony T.C. Chan; K.C. Allen Chan
Cancer Therapy: Clinical
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
Atsushi Aruga; Nobuhiro Takeshita; Yoshihito Kotera; Ryuji Okuyama; Norimasa Matsushita; Takehiro Ohta; Kazuyoshi Takeda; Masakazu Yamamoto
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky; Thomas G. Martin, III; William I. Bensinger; Melissa Alsina; David S. Siegel; Lori A. Kunkel; Alvin F. Wong; Susan Lee; Robert Z. Orlowski; Michael Wang
Predictive Biomarkers and Personalized Medicine
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
Federica Catalanotti; David B. Solit; Melissa P. Pulitzer; Michael F. Berger; Sasinya N. Scott; Tunc Iyriboz; Mario E. Lacouture; Katherine S. Panageas; Jedd D. Wolchok; Richard D. Carvajal; Gary K. Schwartz; Neal Rosen; Paul B. Chapman
Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer
Alessio Amatu; Andrea Sartore-Bianchi; Catia Moutinho; Alessandro Belotti; Katia Bencardino; Giuseppe Chirico; Andrea Cassingena; Francesca Rusconi; Anna Esposito; Michele Nichelatti; Manel Esteller; Salvatore Siena
Correction
Advertisement
